Drug · CHEMBL705

ALITRETINOIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ALITRETINOIN. Drugs and targets, record CHEMBL705. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL705

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ALITRETINOIN; ChEMBL
ChEMBL ID: CHEMBL705; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Panretin, Toctino; ChEMBL
Other names: 9-cis retinoic acid, 9-cis-retinoic acid, AGN 192013, AGN-192013, AGN192013, ALRT-1057, ALRT1057, Alitretinoina, Alitretinoine, BAL-4079, LG-100057, LG100057, LGD-1057, LGD1057, NSC-659772, Retinoic acid 9-cis-form; ChEMBL
DrugBank: DB00523; DrugBank
InChIKey: SHGAZHPCJJPHSC-ZVCIMWCZSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 8 diseases, from ATC and TTD; Open Targets

Targets6

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
RARA	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/5914
RARB	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/5915
RARG	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/5916
RXRA	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/6256
RXRB	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/6257
RXRG	Retinoid receptor	Retinoid receptor agonist	AGONIST	https://conductscience.org/library/genes/6258

Source ChEMBL

Diseases8

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hand eczema	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=EFO_0022959
Kaposi's sarcoma	Approval	TTD	4	2	https://conductscience.org/library/drugs?q=MONDO_0005055
atopic eczema	Approval	ATC	3	2	https://conductscience.org/library/drugs?q=MONDO_0004980
breast cancer	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0007254
cutaneous lupus erythematosus	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005282
lichen planus	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0006572
palmoplantar pustulosis	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0015597
neoplasm	Approval	ATC	1	0	https://conductscience.org/library/drugs?q=MONDO_0005070

Source Open Targets

Trials18

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00817063	Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema	Phase 3	599	2017-11-09	alitretinoin	Its name	ClinicalTrials.gov
NCT05259722	A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema	Phase 3	513	2025-03-14	alitretinoin	Its name	ClinicalTrials.gov
NCT01245140	Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis	Phase 2	33	2017-04-04	alitretinoin	Its name	ClinicalTrials.gov
NCT00124475	Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis	Phase 3	1,035		alitretinoin	Its name	ClinicalTrials.gov
NCT00124436	Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis	Phase 3	300		alitretinoin	Its name	ClinicalTrials.gov
NCT00309621	Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis	Phase 3	250		alitretinoin	Its name	ClinicalTrials.gov
NCT00519675	Alitretinoin in the Treatment of Chronic Hand Eczema	Phase 3	150		alitretinoin	Its name	ClinicalTrials.gov
NCT03026907	Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema	Phase 3	116		alitretinoin	Its name	ClinicalTrials.gov
NCT03026946	Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema	Phase 3	76		alitretinoin	Its name	ClinicalTrials.gov
NCT00002188	A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma	Phase 2	27		alitretinoin	Its name	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alitretinoin 30 mg vs Placebo: Number of Participants Who Responded as Per Patient Global Assessment (PaGA) at End-of-treatment	117 of 298	41 of 298	596	NCT00817063	Trial comparisons
Alitretinoin 30 mg vs Placebo: deaths from any cause	1 of 296	2 of 298	594	NCT00817063	Trial comparisons
Alitretinoin 30 mg vs Placebo: serious adverse events	7 of 296	3 of 298	594	NCT00817063	Trial comparisons
Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: IGA-CHE TS at Week 12.	68 of 250	42 of 253	503	NCT05259722	Trial comparisons
Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: deaths from any cause	0 of 253	0 of 247	500	NCT05259722	Trial comparisons
Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: serious adverse events	5 of 253	12 of 247	500	NCT05259722	Trial comparisons
Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: HECSI-90 at Week 12	96 of 249	65 of 250	499	NCT05259722	Trial comparisons
Alitretinoin 30 mg vs Matching Placebo: serious adverse events	1 of 24	0 of 9	33	NCT01245140	Trial comparisons

Papers from its trials5

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40252681	RESULT	1	PubMed
29997136	DERIVED	1	PubMed
26507685	DERIVED	1	PubMed
25607554	DERIVED	1	PubMed
19659963	DERIVED	1	PubMed

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL705

GET https://conductscience.org/api/drugs/v1/CHEMBL705/targets

API reference For AI assistants